683 Capital Management LLC Has $13.31 Million Stock Position in Fractyl Health, Inc. $GUTS

683 Capital Management LLC grew its position in Fractyl Health, Inc. (NASDAQ:GUTS) by 30.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 6,047,620 shares of the company’s stock after buying an additional 1,397,620 shares during the period. Fractyl Health makes up 0.6% of 683 Capital Management LLC’s portfolio, making the stock its 28th largest position. 683 Capital Management LLC’s holdings in Fractyl Health were worth $13,305,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Nantahala Capital Management LLC acquired a new position in shares of Fractyl Health in the 3rd quarter valued at $19,298,000. Marshall Wace LLP grew its holdings in shares of Fractyl Health by 234.9% in the 4th quarter. Marshall Wace LLP now owns 5,926,745 shares of the company’s stock valued at $13,039,000 after buying an additional 4,156,969 shares during the period. Alyeska Investment Group L.P. acquired a new position in shares of Fractyl Health in the 3rd quarter valued at $8,981,000. Woodline Partners LP grew its holdings in shares of Fractyl Health by 821.1% in the 3rd quarter. Woodline Partners LP now owns 5,506,534 shares of the company’s stock valued at $8,755,000 after buying an additional 4,908,693 shares during the period. Finally, Rosalind Advisors Inc. acquired a new position in shares of Fractyl Health in the 3rd quarter valued at $7,950,000.

Insider Activity at Fractyl Health

In other Fractyl Health news, Director William Bradley bought 68,493 shares of Fractyl Health stock in a transaction that occurred on Wednesday, June 10th. The stock was acquired at an average price of $0.73 per share, for a total transaction of $49,999.89. Following the completion of the acquisition, the director owned 84,622 shares of the company’s stock, valued at $61,774.06. This trade represents a 424.66% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Ian Sheffield bought 35,000 shares of Fractyl Health stock in a transaction that occurred on Wednesday, June 10th. The shares were acquired at an average price of $0.73 per share, with a total value of $25,550.00. Following the acquisition, the director directly owned 35,000 shares of the company’s stock, valued at $25,550. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders bought 171,493 shares of company stock valued at $127,150 in the last quarter. Corporate insiders own 8.52% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on GUTS. Weiss Ratings reissued a “sell (e+)” rating on shares of Fractyl Health in a report on Tuesday, May 12th. Canaccord Genuity Group reissued a “buy” rating and issued a $8.00 price target on shares of Fractyl Health in a report on Thursday, March 26th. Wall Street Zen upgraded shares of Fractyl Health from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Fractyl Health in a report on Thursday, June 4th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $5.40.

Fractyl Health Stock Up 9.5%

Fractyl Health stock opened at $0.85 on Thursday. The stock has a market capitalization of $134.85 million, a PE ratio of -0.66 and a beta of 2.34. Fractyl Health, Inc. has a twelve month low of $0.38 and a twelve month high of $2.45. The company has a quick ratio of 4.28, a current ratio of 4.28 and a debt-to-equity ratio of 1.41. The company has a 50 day moving average of $0.72 and a 200-day moving average of $1.06.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.23. On average, equities research analysts anticipate that Fractyl Health, Inc. will post -0.6 EPS for the current fiscal year.

Fractyl Health Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.